GlassScriptPhysician profile
Adrianna Nottingham
NPI 1386332021
$5,486.53
in general payments reported to CMS, 2019-2025
34 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $3,476 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,459 · Education: $27.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,458.93 |
| Education | $27.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $629.07 | 2024-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $589.05 | 2023-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $414.24 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.19 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $296.16 | 2023-2025 | |
| Qol Medical, LLC | $238.03 | 2024-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $206.18 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $195.30 | 2025 | Omvoh |
| Gilead Sciences, INC. | $168.66 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $162.44 | 2023-2024 | Stelara |
| Madrigal Pharmaceuticals | $142.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $135.50 | 2024-2025 | Endoflip, Eleview |
| Ardelyx, INC. | $117.61 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $111.85 | 2024-2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $93.70 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $92.63 | 2024-2025 | Zenpep |
| Pfizer INC. | $89.23 | 2024 | |
| Enterra Medical, INC. | $85.28 | 2024 | |
| Vivus LLC | $67.30 | 2024-2025 | Qsymia |
| Sandoz INC. | $47.22 | 2024-2025 | |
| Blueprint Medicines Corporation | $45.66 | 2024-2025 | Ayvakit |
| Ironwood Pharmaceuticals, INC | $43.85 | 2024 | |
| Curium US LLC | $34.75 | 2024 | Detectnet |
| Alnylam Pharmaceuticals INC. | $31.45 | 2025 | Givlaari |
| Mallinckrodt Hospital Products INC. | $30.20 | 2025 | Terlivaz |
| Ultragenyx Pharmaceutical INC. | $28.68 | 2025 | Dojolvi |
| Celltrion USA INC. | $27.60 | 2024 | Zymfentra |
| American Regent | $22.20 | 2025 | Injectafer |
| Biocon Biologics INC | $21.75 | 2025 | Hulio |
| Ferring Pharmaceuticals INC. | $20.38 | 2024 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $19.64 | 2024 | Sancuso |
| Braintree Laboratories, INC. | $19.21 | 2024 | Suflave, Sutab |
| Organon LLC | $5.94 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianna Nottingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.